Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO's pharmacovigilance database.

Journal of autoimmunity - 1 Jul 2020

Anquetil Céline, Salem Joe-Elie, Lebrun-Vignes Bénédicte, Touhami Sara, Desbois Anne-Claire, Maalouf Georgina, Domont Fanny, Allenbach Yves, Cacoub Patrice, Bodaghi Bahram, Saadoun David

Abstract excerpt

PURPOSE: Drug-induced uveitis is a rare but sight-threatening condition. We seek to determine the spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors (ICI). METHODS: Retrospective pharmacovigilance study based on adverse drug reactions reported within VigiBase, the WHO international pharmacovigilance database. We included deduplicated individual case safety reports (ICSRs) reported as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to Databases, Factual

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug-Related Side Effects and Adverse Reactions

Share to Immune Checkpoint Inhibitors

Share to Programmed Cell Death 1 Receptor

Share to Uveitis

Share to Uveomeningoencephalitic Syndrome

Share to World Health Organization

Source

Identifiers

PMID: 32303423
DOI: 10.1016/j.jaut.2020.102454

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO's pharmacovigilance database.PMID 32303423Read ↗

Adverse drug reactions associated with the use of biological agentsSemantic proximity Read ↗

Ophthalmic Immune-Related Adverse Events in Cancer Immunotherapy: Tissue-Specific Mechanisms, Clinical Phenotypes, and Consensus-Based Management.Semantic proximity Read ↗

Characterizing Gene Therapy Medicinal Products Post-Marketing Safety Reports based on WHO Pharmacovigilance Database, VigiBaseSemantic proximity Read ↗

Epidemiology and Clinical Features of Anterior Uveitis: a Prospective StudySemantic proximity Read ↗

Research Progress on High-Risk Drugs for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis with Insights from Adverse Drug Reaction Database MiningSemantic proximity Read ↗

Real-world safety profile of Enfortumab Vedotin: A comprehensive pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS)Semantic proximity Read ↗

Demographics, Overlap, and Latency of Severe Cutaneous Adverse Reactions in an FDA DatabaseSemantic proximity Read ↗

Dermatomyositis predominates among checkpoint inhibitor-associated inflammatory myositis phenotypes: a pharmacovigilance disproportionality analysis identifies a class-wide signal.Semantic proximity Read ↗

A real-world pharmacovigilance study of brentuximab vedotin based on the FAERS database from 2011 to 2024Semantic proximity Read ↗

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for TivozanibSemantic proximity Read ↗

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for OsimertinibSemantic proximity Read ↗

A retrospective analysis of drugs associated with the development of cutaneous squamous cell carcinoma reported by patients on the FDA’s adverse events reporting systemSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.